Earnings
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
It’s been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.
With the beginning of a new year, many biopharmaceutical companies are reporting financial raises to advance their pipelines. BioSpace takes a quick look at some of them.
Companies large and small have increased the prices of their drugs so far this week. The drug price increases when the market is seeing high inflation.
The two companies are already looking at the coming year and seeing the potential for their experimental treatment ofATTR, Eplontersen, formerly known as IONIS-TTR-L.
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
The company aims to use the $100 million investment to support biotechnology firms involved in treating mental diseases and longevity projects.
Novartis believes Gyroscope’s investigational Phase II gene therapy for geographic atrophy has the potential to become the first therapy that demonstrates sustained efficacy for GA patients.
Under the terms of the deal, Sanofi is paying Amunix $1 billion up front and up to $225 million in various development milestone payments.
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
PRESS RELEASES